Arinaga S, Akiyoshi T, Tsuji H
Department of Surgery, Kyushu University, Beppu, Japan.
Int J Immunopharmacol. 1988;10(1):47-51. doi: 10.1016/0192-0561(88)90149-x.
Effect of mitomycin C (MMC) administration on the generation of cytotoxic cells induced by in vitro activation of peripheral blood mononuclear cells (PBM) with OK-432, a bacterial immunopotentiator, was studied in patients with various carcinomas. Following i.v. injection of a single dose of 12 mg/m2 MMC, the ability of PBM to generate OK-432 activated killer cells was markedly increased. Thus, the cytotoxic activity observed 7 days after MMC administration was significantly augmented as compared to that before treatment. Therefore, the ability to generate lymphokine activated killer (LAK) cells was examined, and significantly increased capacity was observed 5 and 7 days after MMC injection. Then, the OK-432 activated killer cell activity significantly correlated with the LAK activity. After treatment, the distribution of lymphocyte subsets exhibited a significant decrease in the percentage of OKT8+ cells. Leu-11+ cells were also reduced. The results appear to indicate that the imbalance in T-cell subsets and the increase in the ability to induce LAK cells may be related to the augmenting effect of MMC administration on the generation of OK-432 activated killer cells in cancer patients.
在各类癌症患者中研究了丝裂霉素C（MMC）给药对用细菌免疫增强剂OK-432体外激活外周血单核细胞（PBM）诱导的细胞毒性细胞生成的影响。静脉注射单剂量12mg/m²的MMC后，PBM生成OK-432激活杀伤细胞的能力显著增强。因此，与治疗前相比，MMC给药7天后观察到的细胞毒性活性显著增强。因此，检测了生成淋巴因子激活杀伤（LAK）细胞的能力，在MMC注射后5天和7天观察到能力显著增强。然后，OK-432激活杀伤细胞活性与LAK活性显著相关。治疗后，淋巴细胞亚群的分布显示OKT8+细胞百分比显著降低。Leu-11+细胞也减少。结果似乎表明，T细胞亚群的失衡和诱导LAK细胞能力的增加可能与MMC给药对癌症患者中OK-432激活杀伤细胞生成的增强作用有关。
